Search
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalas the first approved drug for such use since 2014. … Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalLike other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexQuinidine
go.drugbank.com/drugs/DB00908ApprovedThis alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexSuprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: p-2-thenoylhydratropic acid, (±)-2-(p-(2-thenoyl)phenyl)propionic acidABBV-514
go.drugbank.com/drugs/DB17586InvestigationalABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIts indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. … Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).
Trovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnTrovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. … It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCyclothiazide
go.drugbank.com/drugs/DB00606ApprovedAs a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. … This results in an increase in potassium excretion via the sodium-potassium exchange mechanism.
MVR-T3011
go.drugbank.com/drugs/DB17378InvestigationalMVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1